Biogen Idec Inc (BIIB)
BIIB (NASDAQ:Drugs)
$226.85
-1.14
-0.50%
Today's Range: 224.60 - 228.86 |
BIIB Avg Daily Volume: 1,368,900
| Last Update: 05/17/13 - 4:00 PM EDT |
| Volume: 1,243,879 |
| YTD Performance: 55.76%
|
| Open: $228.36 |
| Previous Close: $227.99 |
| 52 Week Range: $126.39 -
$231.99 |
| Oustanding Shares: 237,374,815 |
| Market Cap: 54,119,084,072 |
6-Month Chart
TheStreet Ratings Grade for BIIB
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
11 |
9 |
9 |
9 |
| Moderate Buy |
1 |
1 |
1 |
1 |
| Hold |
9 |
11 |
10 |
11 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
1.90 |
2.10 |
2.05 |
2.10 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
01/18/01 |
| Price Earnings Ratio: |
36.19 |
|
| Price Earnings Comparisons: |
| BIIB |
Sector Avg. |
S&P 500 |
| 36.19 |
36.20 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
35.11%
|
65.83%
|
354.80%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
-13.30 |
0.26 |
0.08 |
| Net Income |
11.80 |
0.42 |
0.12 |
| EPS |
14.30 |
0.72 |
0.20 |
| Earnings for BIIB: |
| EBITDA |
1.38B |
| Revenue |
4.38B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$1.78 |
$2.07 |
$7.88 |
$9.88 |
| Number of Analysts |
4 |
4 |
4 |
4 |
| High Estimate |
$1.96 |
$2.13 |
$8.03 |
$10.71 |
| Low Estimate |
$1.62 |
$1.98 |
$7.77 |
$9.09 |
| Prior Year |
$1.82 |
$1.90 |
$6.53 |
$7.88 |
| Growth Rate (Year over Year) |
-2.06% |
8.82% |
20.64% |
25.45% |
| May 10, 2013 | 12:52 PM EDT
Just a natural change in leadership.
| May 03, 2013 | 7:23 AM EDT
Many of these firms are pouring money into share buybacks -- instead of their long-term pipelines.
| May 01, 2013 | 7:37 AM EDT
Let's take a peek and overnight and morning markets.
May 01, 2013 | 7:30 AM EDT
BIIB was downgraded from Buy to Neutral, Goldman Sachs said. $215 price target. Valuation call, as the stock is up 44% since December.&...
| Apr 26, 2013 | 6:00 PM EDT
Here are two quality names in the sector to watch for a pullback.
| Apr 24, 2013 | 1:16 PM EDT
It’s the only thing that explains today’s action.
| Apr 17, 2013 | 6:20 AM EDT
These four names in particular have made some stunning moves.
| Apr 15, 2013 | 7:43 AM EDT
Keep that in mind as the market reacts to China this morning.
| Apr 11, 2013 | 10:24 AM EDT
Plenty of leadership remains in the health care sector and there’s reason to see further potential.
| Apr 10, 2013 | 3:32 PM EDT
Deep-in-the-money call options on these five names could provide a healthy return.
